$PRAX News

Oppenheimer Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $650

Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $616

Deutsche Bank Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $374

Wedbush Maintains Underperform on Praxis Precision Medicine, Lowers Price Target to $162

Baird Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $400

HC Wainwright & Co. Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $1201

Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint

BTIG Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $810

Praxis Precision's Phase 2/3 POWER1 Study Of Vormatrigine In Focal Onset Seizures Did Not Meet Its Primary Endpoint, Though 50% Response Rate Was Achieved And Seizure Reduction Was More Pronounced At 30 Mg Dose In Second Half Of The Study

HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1245 Price Target

BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $843 Price Target

Truist Securities Maintains Buy on Praxis Precision Medicine, Raises Price Target to $715

Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript

Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $166

BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $843 Price Target

Praxis Precision Medicines (NASDAQ:PRAX) Beats Q1 Estimates as FDA Accepts Two Key Drug Applications

Praxis Precision Medicine Q1 EPS $(3.20) Beats $(3.50) Estimate

Why Is Praxis Precision Stock Soaring Tuesday?

Needham Reiterates Buy on Praxis Precision Medicine, Maintains $510 Price Target